Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
ChemMedChem ; 15(23): 2286-2305, 2020 12 03.
Article in English | MEDLINE | ID: mdl-32937014

ABSTRACT

Since its discovery in 1998, the orexin system has been of interest to the research community as a potential therapeutic target for the treatment of sleep/wake disorders, stress and anxiety disorders, addiction or eating disorders. It consists of two G protein-coupled receptors, the orexin 1 and orexin 2 receptors, and two neuropeptides with agonistic effects, the orexin A and orexin B peptides. Herein we describe our efforts leading to the identification of a promising set of dual orexin receptor antagonists (DORAs) which subsequently went through physiology-based pharmacokinetic and pharmacodynamic modelling>[1] and finally led to the selection of daridorexant, currently in phase 3 clinical trials for the treatment of insomnia disorders.


Subject(s)
Imidazoles/pharmacology , Orexin Receptor Antagonists/pharmacology , Orexin Receptors/metabolism , Pyrrolidines/pharmacology , Sleep Initiation and Maintenance Disorders/drug therapy , Dose-Response Relationship, Drug , Humans , Imidazoles/chemistry , Molecular Structure , Orexin Receptor Antagonists/chemistry , Pyrrolidines/chemistry , Sleep Initiation and Maintenance Disorders/metabolism
2.
J Pharmacol Exp Ther ; 362(3): 489-503, 2017 09.
Article in English | MEDLINE | ID: mdl-28663311

ABSTRACT

The identification of new sleep drugs poses particular challenges in drug discovery owing to disease-specific requirements such as rapid onset of action, sleep maintenance throughout major parts of the night, and absence of residual next-day effects. Robust tools to estimate drug levels in human brain are therefore key for a successful discovery program. Animal models constitute an appropriate choice for drugs without species differences in receptor pharmacology or pharmacokinetics. Translation to man becomes more challenging when interspecies differences are prominent. This report describes the discovery of the dual orexin receptor 1 and 2 (OX1 and OX2) antagonist ACT-541468 out of a class of structurally related compounds, by use of physiology-based pharmacokinetic and pharmacodynamic (PBPK-PD) modeling applied early in drug discovery. Although all drug candidates exhibited similar target receptor potencies and efficacy in a rat sleep model, they exhibited large interspecies differences in key factors determining their pharmacokinetic profile. Human PK models were built on the basis of in vitro metabolism and physicochemical data and were then used to predict the time course of OX2 receptor occupancy in brain. An active ACT-541468 dose of 25 mg was estimated on the basis of OX2 receptor occupancy thresholds of about 65% derived from clinical data for two other orexin antagonists, almorexant and suvorexant. Modeling predictions for ACT-541468 in man were largely confirmed in a single-ascending dose trial in healthy subjects. PBPK-PD modeling applied early in drug discovery, therefore, has great potential to assist in the identification of drug molecules when specific pharmacokinetic and pharmacodynamic requirements need to be met.


Subject(s)
Brain/drug effects , Brain/physiology , Drug Discovery/methods , Imidazoles/pharmacokinetics , Orexin Receptor Antagonists/pharmacokinetics , Pyrrolidines/pharmacokinetics , Animals , CHO Cells , Cricetinae , Cricetulus , Dogs , Dose-Response Relationship, Drug , Double-Blind Method , Humans , Male , Rats , Rats, Wistar
3.
ChemMedChem ; 9(11): 2486-96, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25147058

ABSTRACT

The orexin system consists of two G-protein-coupled receptors, the orexin 1 and orexin 2 receptors, widely expressed in diverse regions of the brain, and two peptide agonists, orexin A and orexin B, which are produced in a small assembly of neurons in the lateral hypothalamus. The orexin system plays an important role in the maintenance of wakefulness. Several compounds (almorexant, SB-649868, suvorexant) have been in advanced clinical trials for treating primary insomnia. ACT-462206 is a new, potent, and selective dual orexin receptor antagonist (DORA) that inhibits the stimulating effects of the orexin peptides at both the orexin 1 and 2 receptors. It decreases wakefulness and increases non-rapid eye movement (non-REM) and REM sleep while maintaining natural sleep architectures in rat and dog electroencephalography/electromyography (EEG/EMG) experiments. ACT-462206 shows anxiolytic-like properties in rats without affecting cognition and motor function. It is therefore a potential candidate for the treatment of insomnia.


Subject(s)
Brain/metabolism , Neurotransmitter Agents/chemistry , Orexin Receptor Antagonists , Pyrrolidines/chemistry , Sulfonamides/chemistry , Animals , Blood-Brain Barrier/metabolism , Dogs , Half-Life , Humans , Madin Darby Canine Kidney Cells , Male , Neurotransmitter Agents/pharmacokinetics , Orexin Receptors/metabolism , Proline/chemistry , Pyrrolidines/pharmacokinetics , Rats , Rats, Wistar , Stereoisomerism , Structure-Activity Relationship , Sulfonamides/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...